Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

Cocrystal Pharma (NASDAQ:COCP) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $12.0 versus the current price of Cocrystal ...

Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and ...

“The absence of any approved norovirus treatments or vaccines creates a substantial market opportunity for Cocrystal,” said James Martin, Cocrystal's CFO and co-CEO. “ With 685 million global cases ...

Cocrystal Pharma announced an extension of enrollment in its Phase 2a human challenge study for the investigational oral influenza PB2 inhibitor, CDI-42344, due to low influenza infection rates ...

Cocrystal Pharma announced positive interim results from a Phase 1 study of its oral pan-viral protease inhibitor CDI-988, designed for the treatment of norovirus and coronavirus infections.

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan ...

BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in a fireside chat at the Zacks SCR Life Sciences Virtual ...

According to data from Benzinga Pro, Cocrystal Pharma shares were up 13.5%, trading at $2.19 at the time of publication. The stock has a 52-week high of $6.78 and a 52-week low of $1.74.

The firm has a market capitalization of $15.57 million, a price-to-earnings ratio of -0.83 and a beta of 2.35. Cocrystal Pharma has a 52-week low of $1.35 and a 52-week high of $3.26.

LHA Investor Relations Jody Cain 310-691-7100 [email protected] Media Contact: JQA Partners Jules Abraham 917-885-7378 [email protected] # # # Source: Cocrystal Pharma, Inc. 2024 GlobeNewswire ...

Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiviral activity against major norovirus variants including GII.4 and GII.17 strains ...